🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Fostering Data Sharing

Search Papers Authors Institutions Grants FAIR About

TheSindex

Fostering Data Sharing

Empowering the data sharing that empowers science — an open, citation-grounded index for datasets.

Product

Search
API
Explore
Rankings

Resources

Methodology
Data Sources
Documentation
Press

Organization

About
Team
Wikidata

© 2026 theSindex. All rights reserved.

Home
Authors
Sarit Assouline

Sarit Assouline

Jewish General Hospital

ORCID: 0000-0002-7638-1589

Also affiliated with McGill University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study”.

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Journal of Clinical Oncology(2020)10.1200/jco.20.00948

N/A

4.9DataRank · unranked

223 citations

Jenny Wu, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, James D’Rozario +23 more

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Blood(2022)10.1182/blood.2021015014

N/A

3.8DataRank · unranked

153 citations

Thomas J. Kipps, Barbara Eichhorst, James D’Rozario, Carolyn Owen, Sarit Assouline +16 more

A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

Leukemia & lymphoma/Leukemia and lymphoma(2022)10.1080/10428194.2022.2148212

N/A

0DataRank · unranked

14 citations

Laura C. Michaelis, Megan Othus, Annette E. Hay, Roland B. Walter, Meagan A. Jacoby +15 more

Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG

Leukemia & lymphoma/Leukemia and lymphoma(2022)10.1080/10428194.2022.2131416

N/A

0DataRank · unranked

0 citations

Ian Thomas, Xu Wang, Cono Ariti, Priyanka Mehta, Mia Sydenham +11 more

Medicinal Chemistry and NMR Driven Discovery of Novel UDP-glucuronosyltransferase 1A Inhibitors That Overcome Therapeutic Resistance in Cells

Journal of Molecular Biology(2023)10.1016/j.jmb.2023.168378

N/A

0DataRank · unranked

5 citations

Anamika Sulekha, Biljana Culjkovic‐Kraljacic, Jadwiga Gasiorek, Edward H. Ruediger, Eric Jolicouer +4 more

CCTG LY18‐A phase I master protocol of novel combination therapy for patients with relapsed or refractory lymphoma ‐ the RGDP‐Venetoclax substudy

Hematological Oncology(2023)10.1002/hon.3164_441

N/A

0DataRank · unranked

1 citations

Diego Villa, Annette E. Hay, Nathalie A. Johnson, Michael Crump, Robert Kridel +10 more